Literature DB >> 11847163

Increased pericardial fluid concentrations of the mature form of adrenomedullin in patients with cardiac remodelling.

K Tambara1, M Fujita, N Nagaya, S Miyamoto, A Iwakura, K Doi, G Sakaguchi, K Nishimura, K Kangawa, M Komeda.   

Abstract

BACKGROUND: There is evidence that adrenomedullin has autocrine or paracrine activities that oppose cardiac remodelling. However, it remains unclear whether it exerts those local functions in heart failure patients.
OBJECTIVE: To investigate the relation between plasma and pericardial fluid concentrations of adrenomedullin and left ventricular haemodynamic variables.
DESIGN: Samples of plasma and pericardial fluid were obtained from 50 patients undergoing cardiac surgery. They were classified into two groups: group N (n = 27) with a left ventricular end diastolic volume index (LVEDVI) < or = 90 ml/m(2); and group R (n = 23) with LVEDVI > 90 ml/m(2). Plasma and pericardial fluid concentrations of total adrenomedullin (tAM) and mature adrenomedullin (mAM) were measured and related to the preoperative haemodynamic variables.
RESULTS: Pericardial fluid concentrations of mAM were much higher than the plasma concentration in both group N and group R (mean (SEM), 10.6 (1.7) v 3.3 (0.2) fmol/ml, p = 0.0001; and 21.2 (2.8) v 3.9 (0.3) fmol/ml, p < 0.0001, respectively). The ratio mAM/tAM in pericardial fluid was significantly higher than in plasma (0.56 (0.02) v 0.28 (0.02), p < 0.0001). Pericardial fluid concentrations of mAM, but not plasma concentrations, were significantly correlated with LVEDVI, left ventricular end systolic volume index, left ventricular ejection fraction, and left ventricular mass index (r = 0.60, 0.63, -0.54, and 0.47, respectively).
CONCLUSIONS: Raised pericardial fluid concentrations of mAM may reflect the actions of adrenomedullin as a local mediator against cardiac remodelling in patients with left ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11847163      PMCID: PMC1767044          DOI: 10.1136/heart.87.3.242

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  33 in total

1.  Plasma adrenomedullin concentrations and cardiac and arterial hypertrophy in hypertension.

Authors:  T Sumimoto; T Nishikimi; M Mukai; K Matsuzaki; E Murakami; S Takishita; A Miyata; H Matsuo; K Kangawa
Journal:  Hypertension       Date:  1997-09       Impact factor: 10.190

2.  Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock.

Authors:  K Nishio; Y Akai; Y Murao; N Doi; S Ueda; H Tabuse; S Miyamoto; K Dohi; N Minamino; H Shoji; K Kitamura; K Kangawa; H Matsuo
Journal:  Crit Care Med       Date:  1997-06       Impact factor: 7.598

3.  Marked elevation of brain natriuretic peptide levels in pericardial fluid is closely associated with left ventricular dysfunction.

Authors:  T Tanaka; K Hasegawa; M Fujita; S I Tamaki; A Yamazato; Y Kihara; R Nohara; S Sasayama
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

4.  Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina.

Authors:  M Fujita; M Ikemoto; M Kishishita; H Otani; R Nohara; T Tanaka; S Tamaki; A Yamazato; S Sasayama
Journal:  Circulation       Date:  1996-08-15       Impact factor: 29.690

5.  Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes.

Authors:  T Tsuruda; J Kato; K Kitamura; K Kuwasako; T Imamura; Y Koiwaya; T Tsuji; K Kangawa; T Eto
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

6.  The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma.

Authors:  K Kitamura; J Kato; M Kawamoto; M Tanaka; N Chino; K Kangawa; T Eto
Journal:  Biochem Biophys Res Commun       Date:  1998-03-17       Impact factor: 3.575

7.  Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide.

Authors:  I Szokodi; P Kinnunen; P Tavi; M Weckström; M Tóth; H Ruskoaho
Journal:  Circulation       Date:  1998-03-24       Impact factor: 29.690

8.  Increased plasma levels of adrenomedullin in patients with heart failure.

Authors:  T Nishikimi; Y Saito; K Kitamura; T Ishimitsu; T Eto; K Kangawa; H Matsuo; T Omae; H Matsuoka
Journal:  J Am Coll Cardiol       Date:  1995-11-15       Impact factor: 24.094

9.  Human pericardial fluid contains the highest amount of endothelin-1 of all mammalian biologic fluids thus far tested.

Authors:  F Horkay; M Laine; I Szokodi; J Leppäluoto; O Vuolteenaho; H Ruskoaho; A Juhász-Nagy; M Tóth
Journal:  J Cardiovasc Pharmacol       Date:  1995       Impact factor: 3.105

10.  Cardiac secretion of adrenomedullin in human heart failure.

Authors:  M Jougasaki; R J Rodeheffer; M M Redfield; K Yamamoto; C M Wei; L J McKinley; J C Burnett
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

View more
  4 in total

Review 1.  Diverse molecular forms of plasma B-type natriuretic peptide in heart failure.

Authors:  Toshio Nishikimi; Naoto Minamino; Kazuwa Nakao
Journal:  Curr Heart Fail Rep       Date:  2011-06

2.  Cohort of estrogen-induced microRNAs regulate adrenomedullin expression.

Authors:  Sarah E Wetzel-Strong; Manyu Li; Scott T Espenschied; Kathleen M Caron
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-11-18       Impact factor: 3.619

3.  Relationship between site of myocardial infarction, left ventricular function and cytokine levels in patients undergoing coronary artery surgery.

Authors:  Ilker Kiris; Sahin Kapan; Cuneyt Narin; Mehmet Ozaydın; Medine Cumhur Cure; Recep Sutcu; Huseyin Okutan
Journal:  Cardiovasc J Afr       Date:  2016 Sep/Oct       Impact factor: 1.167

4.  MicroRNA profiling of pericardial fluid samples from patients with heart failure.

Authors:  Suvi M Kuosmanen; Juha Hartikainen; Mikko Hippeläinen; Hannu Kokki; Anna-Liisa Levonen; Pasi Tavi
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.